Skip to main content
Top
Published in: BMC Immunology 1/2020

Open Access 01-12-2020 | Research article

A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex

Authors: Susanne Axelsson, Anders Magnuson, Anna Lange, Aseel Alshamari, Elisabeth Hultgren Hörnquist, Olof Hultgren

Published in: BMC Immunology | Issue 1/2020

Login to get access

Abstract

Background

The use of anti-B cell based therapies in immune-mediated diseases targeting general B cell markers or molecules important for B cell function has increased the clinical needs of monitoring B cell subpopulations.

Results

We analyzed the expression profile of cell surface markers CD86 and B and T lymphocyte attenuator (BTLA) in B cell subtypes using flow cytometry, including naïve, transitional, switched memory, non-switched memory and double-negative memory B cells and plasmablasts, and investigated the dependence of age and sex in a healthy adult blood donor population. The switched memory B cell subtype displayed a divergent expression of the markers, with increased CD86 and decreased BTLA as compared to non-switched and double negative memory cells, as well as compared to naïve B cells. Plasmablasts expressed highly increased CD86 compared to all other subtypes and a decreased expression of BTLA compared to naïve cells, but still higher compared to the memory cell populations. Transitional B cells had CD86 and BTLA expression similar to the other naïve cells.

Conclusions

We show divergent expression of CD86 and BTLA in memory cells and plasmablasts compared to naïve B cells independent of age and sex. Furthermore, a similarly divergent difference of expression pattern was seen between the memory cell subtypes, altogether indicating that the combination of CD86 and BTLA might be markers for a permissive activation state. We suggest the combination of CD86 and BTLA expression on B cell subtypes as a potentially important tool in monitoring the status of B cell subtypes before and after treatments influencing the B cell compartment.
Literature
1.
go back to reference Bittner S, Ruck T, H. wiendl H, et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10(1):51–66 Review.CrossRef Bittner S, Ruck T, H. wiendl H, et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10(1):51–66 Review.CrossRef
2.
go back to reference Md Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829–36.CrossRef Md Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829–36.CrossRef
3.
go back to reference Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190–5.CrossRef Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190–5.CrossRef
4.
go back to reference Kannan S, Kurupati RK, Doyle SA, et al. BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. Oncotarget. 2015;6(23):19445–55.CrossRef Kannan S, Kurupati RK, Doyle SA, et al. BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. Oncotarget. 2015;6(23):19445–55.CrossRef
5.
go back to reference Abudulai LN, Fernandez S, Corscadden K, et al. Chronic HIV-1 Infection Induces B-Cell Dysfunction That Is Incompletely Resolved by Long-Term Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2016;71(4):381–9.CrossRef Abudulai LN, Fernandez S, Corscadden K, et al. Chronic HIV-1 Infection Induces B-Cell Dysfunction That Is Incompletely Resolved by Long-Term Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2016;71(4):381–9.CrossRef
6.
go back to reference Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993;262(5135):909–11.CrossRef Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993;262(5135):909–11.CrossRef
7.
go back to reference Catalán D, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(2):R68.CrossRef Catalán D, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(2):R68.CrossRef
8.
go back to reference Good KL, Avery DT, Tangye SG. Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol. 2009;182(2):890–901.CrossRef Good KL, Avery DT, Tangye SG. Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol. 2009;182(2):890–901.CrossRef
9.
go back to reference Rau FC, Dieter J, Luo Z, et al. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J Immunol. 2009;183(12):7661–71.CrossRef Rau FC, Dieter J, Luo Z, et al. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J Immunol. 2009;183(12):7661–71.CrossRef
10.
go back to reference Zhao PW, Ma L, Ji HF, et al. The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy. Mediat Inflamm. 2015;2015:762709. Zhao PW, Ma L, Ji HF, et al. The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy. Mediat Inflamm. 2015;2015:762709.
11.
go back to reference De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, et al. Not All Immune Checkpoints Are Created Equal. Front Immunol. 2018;9:1909 Review.CrossRef De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, et al. Not All Immune Checkpoints Are Created Equal. Front Immunol. 2018;9:1909 Review.CrossRef
12.
go back to reference Vendel AC, Calemine-Fenaux J, Izrael-Tomasevic A, et al. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol. 2009;182(3):1509–17.CrossRef Vendel AC, Calemine-Fenaux J, Izrael-Tomasevic A, et al. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol. 2009;182(3):1509–17.CrossRef
13.
go back to reference Thibult ML, Rivals JP, Mamessier E, et al. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells. J Mol Med (Berl). 2013;91(2):195–205.CrossRef Thibult ML, Rivals JP, Mamessier E, et al. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells. J Mol Med (Berl). 2013;91(2):195–205.CrossRef
14.
go back to reference Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38 Review.CrossRef Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38 Review.CrossRef
15.
go back to reference Flanagan KL, Fink AL, Plebanski M, et al. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu Rev Cell Dev Biol. 2017;33:577–99 Review.CrossRef Flanagan KL, Fink AL, Plebanski M, et al. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu Rev Cell Dev Biol. 2017;33:577–99 Review.CrossRef
16.
go back to reference Papathanassoglou E, Middleton N, Benbenishty J, et al. Systematic review of gender- dependent outcomes in sepsis. Nurs Crit Care. 2017;22(5):284–92 Review.CrossRef Papathanassoglou E, Middleton N, Benbenishty J, et al. Systematic review of gender- dependent outcomes in sepsis. Nurs Crit Care. 2017;22(5):284–92 Review.CrossRef
17.
go back to reference Covens K, Verbinnen B, Geukens N, et al. Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood. 2013;121(26):5176–83.CrossRef Covens K, Verbinnen B, Geukens N, et al. Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood. 2013;121(26):5176–83.CrossRef
18.
go back to reference GP GPS, R. Ettinger R, Shirota Y, et al. Identification and characterization of circulating human transitional B cells. Blood. 2005;105(11):4390–8.CrossRef GP GPS, R. Ettinger R, Shirota Y, et al. Identification and characterization of circulating human transitional B cells. Blood. 2005;105(11):4390–8.CrossRef
19.
go back to reference Palanichamy A, Barnard J, Zheng B, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009;182(10):5982–93.CrossRef Palanichamy A, Barnard J, Zheng B, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009;182(10):5982–93.CrossRef
20.
go back to reference Agrawal S, Smith SA, Tangye SG, et al. Transitional B cell subsets in human bone marrow. Clin Exp Immunol. 2013;174(1):53–9.CrossRef Agrawal S, Smith SA, Tangye SG, et al. Transitional B cell subsets in human bone marrow. Clin Exp Immunol. 2013;174(1):53–9.CrossRef
21.
go back to reference Kasprowicz DJ, Kohm AP, Berton MT, et al. Stimulation of the B cell receptor, CD86 (B7-2), and the beta 2-adrenergic receptor intrinsically modulates the level of IgG1 and IgE produced per B cell. J Immunol. 2000;165(2):680–90.CrossRef Kasprowicz DJ, Kohm AP, Berton MT, et al. Stimulation of the B cell receptor, CD86 (B7-2), and the beta 2-adrenergic receptor intrinsically modulates the level of IgG1 and IgE produced per B cell. J Immunol. 2000;165(2):680–90.CrossRef
22.
go back to reference Fink K. Origin and Function of Circulating Plasmablasts during Acute Viral Infections. Front Immunol. 2012;3:78.CrossRef Fink K. Origin and Function of Circulating Plasmablasts during Acute Viral Infections. Front Immunol. 2012;3:78.CrossRef
23.
go back to reference Hu F, Zhang W, Shi L, et al. Impaired CD27+IgD+ B Cells With Altered Gene Signature in Rheumatoid Arthritis. Front Immunol. 2018;9:626.CrossRef Hu F, Zhang W, Shi L, et al. Impaired CD27+IgD+ B Cells With Altered Gene Signature in Rheumatoid Arthritis. Front Immunol. 2018;9:626.CrossRef
24.
go back to reference van Duin D, Allore HG, Mohanty S, et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis. 2007;195(11):1590–7.CrossRef van Duin D, Allore HG, Mohanty S, et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis. 2007;195(11):1590–7.CrossRef
25.
go back to reference Oki M, Watanabe N, Owada T, et al. A functional polymorphism in B and T lymphocyte attenuator is associated with susceptibility to rheumatoid arthritis. Clin Dev Immunol. 2011;2011:305656.CrossRef Oki M, Watanabe N, Owada T, et al. A functional polymorphism in B and T lymphocyte attenuator is associated with susceptibility to rheumatoid arthritis. Clin Dev Immunol. 2011;2011:305656.CrossRef
26.
go back to reference Menezes SM, Decanine D, Brassat D, et al. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. J Neuroinflammation. 2014;11:18.CrossRef Menezes SM, Decanine D, Brassat D, et al. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. J Neuroinflammation. 2014;11:18.CrossRef
28.
go back to reference Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
Metadata
Title
A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex
Authors
Susanne Axelsson
Anders Magnuson
Anna Lange
Aseel Alshamari
Elisabeth Hultgren Hörnquist
Olof Hultgren
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2020
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-020-00343-2

Other articles of this Issue 1/2020

BMC Immunology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.